CN110982737A - Biofilm lactic acid bacteria agent for dogs and preparation method thereof - Google Patents
Biofilm lactic acid bacteria agent for dogs and preparation method thereof Download PDFInfo
- Publication number
- CN110982737A CN110982737A CN201911219339.XA CN201911219339A CN110982737A CN 110982737 A CN110982737 A CN 110982737A CN 201911219339 A CN201911219339 A CN 201911219339A CN 110982737 A CN110982737 A CN 110982737A
- Authority
- CN
- China
- Prior art keywords
- dogs
- lactic acid
- acid bacteria
- biofilm
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 241000894006 Bacteria Species 0.000 title claims abstract description 46
- 241000282472 Canis lupus familiaris Species 0.000 title claims abstract description 45
- 239000004310 lactic acid Substances 0.000 title claims abstract description 37
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 37
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000001963 growth medium Substances 0.000 claims abstract description 31
- 239000007788 liquid Substances 0.000 claims abstract description 28
- 241000186660 Lactobacillus Species 0.000 claims abstract description 17
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 17
- 230000001580 bacterial effect Effects 0.000 claims abstract description 13
- 238000004113 cell culture Methods 0.000 claims abstract description 5
- 230000007480 spreading Effects 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 5
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 241000251555 Tunicata Species 0.000 claims description 3
- 239000006872 mrs medium Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 241000282465 Canis Species 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 235000019621 digestibility Nutrition 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001591005 Siga Species 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of lactic acid bacteria, in particular to a biofilm-state lactic acid bacteria agent for dogs and a preparation method thereof, wherein the preparation method comprises the following steps: inoculating lactobacillus into an improved MRS culture medium for activated culture, transferring the culture solution, flatly spreading the culture solution into a cell culture plate, and standing for culture to obtain an enveloped bacterial solution; and preparing the tunica membranaceus bacterial liquid into a biofilm-state lactic acid bacteria agent for dogs. The film-coated lactic acid bacteria agent prepared by the preparation method can obviously improve the average daily gain of dogs, reduce the material-weight ratio and have obvious regulation effect on canine intestinal flora.
Description
Technical Field
The invention relates to the technical field of lactic acid bacteria, in particular to a biofilm-state lactic acid bacteria agent for dogs and a preparation method thereof.
Background
Dogs are one of the earliest domesticated animals and are currently the most prevalent companion animals in the world. The scale of feeding is extremely large worldwide. Such mass raising is due to great value of dogs, such as high intellectual level, social behavior, more developed sense organs than human, playing various roles in human society, often trained as working dogs, etc. Thus, the health of dogs is receiving increasing attention.
The health of canines is largely dependent on their gastrointestinal microorganisms, the composition and activity of their gut microflora being associated with several diseases. This microbial ecosystem plays a role in a variety of aspects, such as influencing the absorption and metabolism of nutrients, the nutrition and the protective function of the host. Any disturbance of the gastrointestinal flora may lead to the development of a number of diseases, such as diarrhoea, allergy, obesity and stress syndrome. Different treatments are being developed in order to balance the flora structure and to combat infections, among which probiotic therapy is of great interest.
Biofilm refers to a mass of bacterial biofilm-like material formed by bacteria adhering to a contact surface, secreting polysaccharide matrices, fibrin, lipoprotein, etc., and wrapping themselves around them. Microorganisms in the natural state often live in the form of a biofilm state, and have the advantages which are incomparable with the traditional culture state. At present, research on harmful microbial biofilms is more, research on probiotics, particularly lactobacillus biofilms is very rare, the probiotics and lactobacillus biofilms are suitable for dogs, average daily gain of dogs can be effectively improved, and no biofilm with an obvious regulation effect on canine intestinal flora is reported.
Disclosure of Invention
In view of the above, the present invention aims to provide a biofilm lactic acid bacterial agent for dogs and a preparation method thereof. The biomembrane state lactic acid bacteria agent provided by the invention can effectively improve the average daily gain of dogs and has an obvious regulation effect on canine intestinal flora.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides a preparation method of a biofilm lactic acid bacteria agent for dogs, which comprises the following steps:
inoculating lactobacillus into an improved MRS culture medium for activated culture, transferring the culture solution, flatly spreading the culture solution into a cell culture plate, and standing for culture to obtain an enveloped bacterial solution; preparing the tunicate bacteria liquid into a biofilm lactic acid bacteria agent for dogs;
the improved MRS culture medium comprises a liquid improved MRS culture medium and a solid improved MRS culture medium, wherein the liquid improved MRS culture medium comprises the following components: 10g/L of peptone, 5g/L of yeast extract, 2g/L of diammonium citrate, 20g/L of glucose and MgSO4·7H20.58g/L of O, 10g/L of beef extract and K2HPO4·3H2O2 g/L, sodium acetate 5g/L, Tween 801 g/L, MnSO4·4H2O0.25 g/L, 0.1-1% signal factor AI-2; the solid modified MRS culture medium consists of the components and agar of 16 g/L.
In some embodiments, the Lactobacillus is Lactobacillus plantarum LR-1.
In some embodiments, the liquid modified MRS medium consists of: 10g/L of peptone, 5g/L of yeast extract, 2g/L of diammonium citrate, 20g/L of glucose and MgSO4·7H20.58g/L of O, 10g/L of beef extract and K2HPO4·3H2O2 g/L, sodium acetate 5g/L, Tween 801 g/L, MnSO4·4H2O0.25 g/L, 0.5% signal factor AI-2; the solid modified MRS culture medium consists of the components and agar of 16 g/L.
In some embodiments, the activated culture is specifically that lactobacillus is inoculated in a solid modified MRS culture medium for streak culture, and then a single colony is taken to be cultured in a liquid modified MRS culture medium.
In some embodiments, the streaking culture is a three-zone streaking culture.
In some embodiments, the transferring is specifically: and adding the liquid modified MRS culture medium into the culture solution according to the volume ratio of 1: 100.
In some embodiments, the temperature of the static culture is 30-37 ℃, and the static culture is carried out until the viable count is more than or equal to 1 × 108CFU/mL. In some embodiments, the temperature of the static culture is 30 ℃, and the static culture is carried out until the viable count is 1 × 108CFU/mL。
In some embodiments, the preparation of the biofilm bacteria solution into the biofilm lactic acid bacteria agent for dogs specifically comprises: and (3) taking the membrane-state bacterium liquid, and performing refrigerated centrifugation, enrichment, heavy suspension and freeze drying to obtain the biofilm-state lactic acid bacteria agent for dogs.
Further, the temperature of the freezing centrifugation is 4-8 ℃, the time is 5-10 min, and the rotating speed is 4000-6000 g. In some embodiments, the temperature of the refrigerated centrifugation is 4 ℃, the time is 5min, and the rotation speed is 5000 g.
In some embodiments, the resuspension is performed with skim milk powder. In some embodiments, the volume ratio of the skim milk powder to the enriched liquid in the enveloped state is 1: 10. In some embodiments, the number of viable bacteria after resuspension is greater than or equal to 1X 109CFU/mL. In some embodiments, the number of viable bacteria after resuspension is 1X 109CFU/mL。
In some embodiments, the temperature of the freeze drying is-80 ℃, and the time of the freeze drying is 36-48 h.
The invention also provides the biofilm state lactic acid bacteria agent for dogs prepared by the preparation method.
In some specific embodiments, the formulation of the biofilm lactic acid bacteria agent for dogs is freeze-dried powder.
The invention provides a dog biofilm lactic acid bacteria agent and a preparation method thereof, wherein the preparation method of the dog biofilm lactic acid bacteria agent comprises the following steps: inoculating lactobacillus into a solid modified MRS culture medium for streak culture, taking a single colony to culture in a liquid modified MRS culture medium, and then transferring and spreading a culture solution into a cell culture plate for standing culture to obtain an enveloped bacterial solution; and (3) taking the membrane-state bacteria liquid for freezing and centrifuging, enriching, resuspending and freeze-drying to obtain the biological membrane-state lactic acid bacteria agent for dogs. The invention adopts a specific process combined with an improved MRS culture medium to culture the lactobacillus, and the prepared tunica mucosa lactic acid bacteria agent can obviously improve the average daily gain of dogs, reduce the material-weight ratio and have obvious regulation effect on canine intestinal flora
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 shows canine blood IgG content in example 3;
FIG. 2 shows canine blood sIgA in example 3;
FIG. 3 shows the blood IL-6 levels in dogs of example 3;
FIG. 4 shows the canine blood TNF- α levels in example 3;
FIG. 5 shows the blood SOD levels in dogs according to example 3;
FIG. 6 shows the malondialdehyde content in blood of dogs in example 3;
FIG. 7 shows the performance of the canine fecal microflora at the phylum level in example 4;
FIG. 8 shows the performance of the canine fecal microbiota at class level in example 4;
FIG. 9 shows the behavior of the canine fecal microbial flora at the genus level in example 4.
Detailed Description
The invention discloses a biofilm lactic acid bacteria agent for dogs and a preparation method thereof, and a person skilled in the art can use the content for reference and appropriately improve process parameters to realize the purpose. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
The invention is further illustrated by the following examples:
EXAMPLE 1 Lactobacillus plantarum LR-1 activation and preparation of biofilm-State lyophilized powder
Preparing a liquid modified MRS culture medium, a solid modified MRS culture medium and 0.85% of normal saline, sterilizing corresponding articles, drying and sterilizing an aseptic operation table.
The liquid modified MRS culture medium consists of the following components: 10g/L of peptone, 5g/L of yeast extract, 2g/L of diammonium citrate, 20g/L of glucose and MgSO4·7H20.58g/L of O, 10g/L of beef extract and K2HPO4·3H2O2 g/L, sodium acetate 5g/L, Tween 801 g/L, MnSO4·4H2O0.25 g/L, 0.5% signal factor AI-2; the solid modified MRS culture medium consists of the components and agar of 16 g/L.
Activated Lactobacillus plantarum LR-1: taking Lactobacillus plantarum LR-1 from a glycerol tube a little, standing and culturing at 30 ℃ until a single colony grows out, selecting the single colony in a liquid modified MRS culture medium, standing and culturing at 30 ℃ for 24h, then transferring the single colony with the liquid modified MRS culture medium according to the volume ratio of 1:100, and spreading the single colony in a cell culture plate, standing and culturing at 30 ℃ until the viable count reaches 108CFU/mL, biofilm formation.
Collecting 10mL of the bacterial liquid, centrifuging at 4 ℃ for 5min at 5000g, discarding the supernatant, washing with sterile physiological saline once, centrifuging to collect bacterial sludge, suspending in 1mL of sterile skim milk, placing in a sterile penicillin bottle, and sealing with sterile gauze. Placing the penicillin bottle containing the bacterial liquid and a vacuum freeze dryer tray together in a refrigerator at the temperature of 80 ℃ below zero for pre-freezing for 2 to 3 hours, and then placing the penicillin bottle and the vacuum freeze dryer tray into a vacuum freeze dryer for freeze drying for 36 hours to obtain bacterial powder, namely the biofilm peptide lactic acid bacteria agent.
Example 2 Effect of the biofilm-state lactic acid bacteria agent of the present invention on body weight and digestibility
1. Feeding with lactobacillus
Lactic acid prepared in example 1The microbial inoculum is diluted by 1mL of sterile normal saline, and the total bacterial count is 109CFU/mL, the total volume is 1mL, a 4-month-old beagle dog is fed by adopting an injector, 5 dogs in a control group, a floating state treatment group and a capsule state treatment group respectively and a floating state treatment group are adopted, and the preparation method of the floating state is as follows: inoculating lactobacillus into a solid modified MRS culture medium for streak culture, taking a single colony to culture in a liquid modified MRS culture medium, transferring a culture solution into a test tube, and performing shake culture at 30-37 ℃ until the viable count is at least 108CFU/mL to obtain planktonic bacteria liquid; taking the floating state bacterial liquid for refrigerated centrifugation, enrichment, heavy suspension and freeze drying until the viable count is at least 109CFU/mL, which is the planktonic lactic acid bacteria agent for dogs. The control group was fed the same volume of sterile normal saline.
2. Body weight determination
The body weights of the tested dogs are detected and recorded, and the average daily gain and the material weight ratio are calculated, and the results are shown in table 1.
TABLE 1
Note: the different letters of the shoulder marks in the same row show significant differences (P < 0.05).
From the results in table 1, it can be seen that the modal treated group of the invention significantly increased the average daily gain of dogs (P <0.05) and significantly decreased the feed-to-weight ratio (P <0.05) compared to the control group and the planktonic treated group.
3. Determination of digestibility
Dog faeces of the control and test groups were collected at 50g per sample and 7 items of moisture, crude protein, crude fat, crude fibre, calcium, total phosphorus and ash were measured separately and the total raw composition of the feed was compared to calculate the digestibility of 6 of these items as shown in table 2.
TABLE 2
Note: the shoulder marks in the same row show significant differences (P <0.05) in different lower case letters, and show significant differences (P < 0.01) in different upper case letters.
As can be seen from Table 2, the biofilm freeze-dried lactic acid bacteria for dogs can remarkably improve the digestibility of crude protein, crude fat, crude fiber and total phosphorus, and has a remarkable difference (P is less than 0.05) compared with the planktonic treatment group; significant difference in crude protein digestibility compared to the control group (P < 0.05); the total phosphorus digestibility of the fat, the fiber and the phosphorus were significantly different from that of the control group (P < 0.05).
Example 3 Effect of the biofilm lactic acid bacteria agent of the present invention on blood indices
1. Feeding with lactobacillus
The same procedure as in example 2 was used for feeding the lactic acid bacteria.
2. Blood index measurement
ELISA kit is used for detecting the content of IgG, sIgA, IL-6 and TNF- α in the canine serum, and biochemical index detection kit is used for detecting the content of SOD and malondialdehyde.
The results are shown in FIGS. 1 to 6, which indicate that the mean IgG content of the treated group was increased.
Example 4 microbial diversity in feces after dogs received biofilm lactic acid bacteria
1. Feeding with lactobacillus
The same procedure as in example 2 was used for feeding the lactic acid bacteria.
2. Feces collection
Feces were collected at 28 days after feeding, 50g of each sample, and frozen in liquid nitrogen.
3. Genome extraction and library construction
And extracting a genome of the collected sample, constructing a library of the qualified sample for detection, performing cluster preparation and sequencing on the qualified library, and performing corresponding biological information analysis on data obtained by off-machine analysis.
4. Data analysis
The data of the off-line terminal is filtered to remove low-quality reads and leave high-quality Clean data; sample species complex analysis as well as inter-group species difference analysis were performed based on OUT and species annotation results. Diversity was determined based on the sequence of the 16SrDNA variable region. The results are shown in FIGS. 7 to 9. As can be seen from the graphs in FIGS. 7 to 9, the microbial diversity in the dog feces of the membrane-state treated group is remarkably changed, wherein the content of lactobacillus is remarkably increased, which indicates that the lactobacillus of the membrane-state treated group has more field planting numbers, and thus the membrane-state treated group has a better regulation effect on dog intestinal flora.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A preparation method of a biofilm lactic acid bacteria agent for dogs is characterized by comprising the following steps:
inoculating lactobacillus into an improved MRS culture medium for activated culture, transferring the culture solution, flatly spreading the culture solution into a cell culture plate, and standing for culture to obtain an enveloped bacterial solution; preparing the tunicate bacteria liquid into a biofilm lactic acid bacteria agent for dogs;
the improved MRS culture medium comprises a liquid improved MRS culture medium and a solid improved MRS culture medium, wherein the liquid improved MRS culture medium comprises the following components: 10g/L of peptone, 5g/L of yeast extract, 2g/L of diammonium citrate, 20g/L of glucose and MgSO4·7H20.58g/L of O, 10g/L of beef extract and K2HPO4·3H2O2 g/L, sodium acetate 5g/L, Tween 801 g/L, MnSO4·4H2O0.25 g/L, 0.1-1% signal factor AI-2; the solid modified MRS culture medium consists of the components and agar of 16 g/L.
2. The method according to claim 1, wherein the lactobacillus is Lactobacillus plantarum LR-1.
3. The preparation method according to claim 1, wherein the liquid MRS medium consists of the following components: 10g/L of peptone, 5g/L of yeast extract and 2g of diammonium citrateL, glucose 20g/L, MgSO4·7H20.58g/L of O, 10g/L of beef extract and K2HPO4·3H2O2 g/L, sodium acetate 5g/L, Tween 801 g/L, MnSO4·4H2O0.25 g/L, 0.1-1% signal factor AI-2; the solid modified MRS culture medium consists of the components and agar of 16 g/L.
4. The preparation method according to claim 1, wherein the activated culture is specifically that lactobacillus is inoculated in a solid modified MRS culture medium for streak culture, and then a single colony is taken to be cultured in a liquid modified MRS culture medium.
5. The preparation method according to claim 1, wherein the switching is specifically to add the liquid modified MRS medium to the culture solution according to a volume ratio of 1: 100.
6. The method according to claim 1, wherein the temperature of the static culture is 30 to 37 ℃ and the static culture is carried out until the viable count is not less than 1X 108CFU/mL。
7. The preparation method according to claim 1, wherein the preparation of the tunicates into the biofilm-state lactic acid bacteria for dogs specifically comprises: and (3) taking the membrane-state bacterium liquid, and performing refrigerated centrifugation, enrichment, heavy suspension and freeze drying to obtain the biofilm-state lactic acid bacteria agent for dogs.
8. The preparation method according to claim 7, wherein the temperature of the refrigerated centrifugation is 4-8 ℃, the time is 5-10 min, and the rotating speed is 4000-6000 g; the number of the live bacteria after heavy suspension is more than or equal to 1 multiplied by 109CFU/mL; the temperature of the freeze drying is-80 ℃, and the time is 36-48 h.
9. Biofilm-state lactic acid bacteria agent for dogs prepared by the preparation method as described in any one of claims 1 to 8.
10. The biofilm lactic acid bacteria agent for dogs as claimed in claim 9, wherein the dosage form of the biofilm lactic acid bacteria agent for dogs is freeze-dried powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911219339.XA CN110982737A (en) | 2019-12-03 | 2019-12-03 | Biofilm lactic acid bacteria agent for dogs and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911219339.XA CN110982737A (en) | 2019-12-03 | 2019-12-03 | Biofilm lactic acid bacteria agent for dogs and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110982737A true CN110982737A (en) | 2020-04-10 |
Family
ID=70089673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911219339.XA Pending CN110982737A (en) | 2019-12-03 | 2019-12-03 | Biofilm lactic acid bacteria agent for dogs and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110982737A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113632762A (en) * | 2021-07-06 | 2021-11-12 | 云南农业大学 | Method for improving working performance of Kunming dog puppy by using fecal strain transplantation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105624097A (en) * | 2016-03-16 | 2016-06-01 | 中国农业大学 | Application of AI-2 in improving bacteria acid resistance and/or oxygen resistance and method for improving bacteria acid resistance and/or oxygen resistance |
| CN109517764A (en) * | 2019-01-10 | 2019-03-26 | 西华大学 | A kind of biofilm state lactobacillus-fermented microbial inoculum and preparation method thereof |
| CN110193030A (en) * | 2019-04-29 | 2019-09-03 | 山东苏柯汉生物工程股份有限公司 | A kind of dog probiotics and preparation method thereof |
| CN110507673A (en) * | 2019-09-17 | 2019-11-29 | 江苏农牧科技职业学院 | A kind of dog is with lactic acid bacteria and signaling molecule combination preparation and preparation method thereof |
-
2019
- 2019-12-03 CN CN201911219339.XA patent/CN110982737A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105624097A (en) * | 2016-03-16 | 2016-06-01 | 中国农业大学 | Application of AI-2 in improving bacteria acid resistance and/or oxygen resistance and method for improving bacteria acid resistance and/or oxygen resistance |
| CN109517764A (en) * | 2019-01-10 | 2019-03-26 | 西华大学 | A kind of biofilm state lactobacillus-fermented microbial inoculum and preparation method thereof |
| CN110193030A (en) * | 2019-04-29 | 2019-09-03 | 山东苏柯汉生物工程股份有限公司 | A kind of dog probiotics and preparation method thereof |
| CN110507673A (en) * | 2019-09-17 | 2019-11-29 | 江苏农牧科技职业学院 | A kind of dog is with lactic acid bacteria and signaling molecule combination preparation and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘蕾等: "tuf基因同源超表达对植物乳杆菌LR-1生理行为的影响", 《食品科学》 * |
| 刘蕾等: "基于AI-2介导的类植物乳杆菌生物被膜态与浮游态抗胁迫能力比较与分析", 《食品科学》 * |
| 刘蕾等: "类植物乳杆菌L-ZS9生物被膜态的黏附能力及形成影响因素", 《食品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113632762A (en) * | 2021-07-06 | 2021-11-12 | 云南农业大学 | Method for improving working performance of Kunming dog puppy by using fecal strain transplantation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111235070B (en) | Breast milk infant source lactobacillus plantarum BF _15 and application thereof | |
| CN102533618B (en) | Lactobacillus plantarum CCFM8724 and application thereof | |
| CN102747003B (en) | Screening and application of probiotic Enterococcus faecium | |
| CN1186440C (en) | New bifidobacteria preventing diarrhea caused by pathogenic bacteria | |
| CN113088463B (en) | Lactobacillus acidophilus with probiotic characteristics and application thereof | |
| CN112195139B (en) | Lactobacillus plantarum strain LDVS007 and application thereof | |
| CN109481476B (en) | Application of lactobacillus fermentum CQPC04 in preparing food or medicine for improving ulcerative colitis | |
| CN108384735A (en) | Lactobacillus plantarum CCFM1019, its fermented food and its application in medicine preparation | |
| CN112094790B (en) | Lactobacillus plantarum LP45 live bacterium preparation for regulating intestinal flora and application thereof | |
| CN103911306B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN103911305B (en) | Lactobacillus crispatus bacterial strain and uses thereof | |
| CN103911309B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN103911308A (en) | Lactobacillus crispatus strain and its uses | |
| CN112239739B (en) | Lactobacillus plantarum capable of relieving ETEC (enterotoxigenic enterobacteria) induced diarrhea and application thereof | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN112574924B (en) | Bacillus subtilis strain, microecological preparation and application thereof | |
| CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
| CN103911307B (en) | Lactobacillus crispatus bacterial strain and uses thereof | |
| CN110982737A (en) | Biofilm lactic acid bacteria agent for dogs and preparation method thereof | |
| CN114908009B (en) | Lactobacillus mucilaginosus PR63 and application thereof | |
| CN112538441B (en) | Lactobacillus reuteri CCFM1144 for relieving diarrhea caused by ETEC and application thereof | |
| CN109619183B (en) | Application of lactobacillus plantarum CQPC03 in preparation of medicine for preventing oxidative damage of liver | |
| JP2017012163A (en) | Lactobacillus plantarum llp5193 with high acid- and bile-resistance and high cell attaching ability and products containing it as the effective ingredient | |
| CN104694441A (en) | Lactobacillus plantarum suitable for being made into freeze-dried powder | |
| CN116694503B (en) | Lactobacillus plantarum Lp-HZ55 with bowel relaxing and immunity improving functions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |